National Center for Medical Intelligence

Bluesight Appoints Jason Vander Meer as Chief Product Officer to Expand Medication Intelligence Suite

Retrieved on: 
Thursday, October 26, 2023
Barclays, National Center for Medical Intelligence, Medication, Acquisition, Product management, Health, Software, Meer, GoCanvas, Pharmacy, Hospital, Safety, Lehman Brothers, Management, Litera

ALEXANDRIA, Va., Oct. 26, 2023 /PRNewswire/ -- Bluesight, the leader in Medication Intelligence™ solutions, announced today the appointment of Jason Vander Meer to Chief Product Officer. Jason brings a wealth of experience and a proven track record in software and product development to his new position at Bluesight, making him a valuable addition to the company's leadership team.

Key Points: 
  • New leader of product strategy and development to drive innovation, support company's growth plans
    ALEXANDRIA, Va., Oct. 26, 2023 /PRNewswire/ -- Bluesight, the leader in Medication Intelligence™ solutions, announced today the appointment of Jason Vander Meer to Chief Product Officer.
  • In this new position, Vander Meer will be responsible for supporting the company's suite of Medication Intelligence solutions and developing new products that improve efficiency, reduce medication costs, and increase compliance and safety.
  • Prior to joining Bluesight, Jason served as the Chief Product Officer at GoCanvas and Litera.
  • "I am thrilled to be working with Bluesight, an innovative industry leader dedicated to going above and beyond for its customers and providing valuable insights to enhance patient outcomes within the healthcare ecosystem," said Jason Vander Meer, Chief Product Officer.

Adlumin Closes $70M Series B, Fueling its Mission of Bringing Enterprise-Grade Security to Mid-Market Organizations

Retrieved on: 
Thursday, October 26, 2023
Technology, Finance, Security, Banking, Other Technology, Professional Services, Software, Networks, Internet, Data Management, Insurance, Intelligence, National Center for Medical Intelligence, SIEM, Face, MDR, News, Organization, GDP, Growth, Private sector, School, Member of the Scottish Parliament, Information technology, National Center for the Middle Market, MSSP, Cryptocurrency, Risk management, Online shopping

But going beyond basic cybersecurity at these organizations has been generally overlooked or sadly out of reach.

Key Points: 
  • But going beyond basic cybersecurity at these organizations has been generally overlooked or sadly out of reach.
  • The data these organizations must protect is just as sensitive, and the threats they face are just as severe as their larger counterparts.
  • Adlumin also works closely with managed service providers (MSPs) and managed security service providers (MSSPs) who use its platform to serve their customers.
  • Regardless of who operates the platform, Adlumin delivers end-user organizations unmatched visibility into their security posture.

BlueDot partners with Japan to revolutionize global infectious disease surveillance with innovative early warning system

Retrieved on: 
Wednesday, July 5, 2023
Science, National Center for Medical Intelligence, Policy, Infection, Partnership, BlueDot, Intelligence, Research, Preventive healthcare, Pharmaceutical industry, Vaccine

TORONTO, July 5, 2023 /PRNewswire-PRWeb/ -- BlueDot Inc., a global leader in infectious disease intelligence, announced today that it has signed an agreement with the National Center for Global Health and Medicine (NCGM) of Japan. The collaboration will draw from BlueDot's strengths in integrating artificial and human intelligence to strengthen Japan's readiness and resilience to outbreaks of known and novel infectious diseases.

Key Points: 
  • TORONTO, July 5, 2023 /PRNewswire-PRWeb/ -- BlueDot Inc. , a global leader in infectious disease intelligence, announced today that it has signed an agreement with the National Center for Global Health and Medicine (NCGM) of Japan.
  • The collaboration will draw from BlueDot's strengths in integrating artificial and human intelligence to strengthen Japan's readiness and resilience to outbreaks of known and novel infectious diseases.
  • Under this new partnership, NCGM will leverage BlueDot's global infectious disease intelligence and subject-matter expertise to identify emerging threats earlier, bolster the efficiency of their global horizon scanning activities, and increase the depth and timeliness of their risk assessments.
  • This intelligence will support the Disease Control and Prevention Center within NCGM and will aid their research, policy development, and infectious disease control and prevention programs.

Bluesight Hosts Third Diversion Symposium to Explore Key Topics Related to Drug Diversion Prevention

Retrieved on: 
Tuesday, February 28, 2023
Other Health, Hospitals, Health, Pharmaceutical, Health Technology, Linda, Pharmacy technician, Accreditation Council for Pharmacy Education, MBA, Accreditation Council, Hospital, ACPE, Doctor of Pharmacy, National Center for Medical Intelligence, Serious case review, Medication, Pharmacy, Patient safety, Pharmacist, Accreditation, Nursing, Medical device

On March 22nd, 2023 from 12 pm ET to 3pm ET, Bluesight®, The Medication Intelligence™ Company, will host its third Diversion Symposium.

Key Points: 
  • On March 22nd, 2023 from 12 pm ET to 3pm ET, Bluesight®, The Medication Intelligence™ Company, will host its third Diversion Symposium.
  • This virtual symposium will consist of three webinars featuring pharmacy leaders from across the country.
  • These sessions will emphasize best practices in drug diversion prevention and allow participants to take a comprehensive look into different aspects of diversion monitoring.
  • “After a year off, we’re thrilled to be hosting the Diversion Symposium once again,” said Kevin MacDonald, CEO of Bluesight.

New Report from BluesightⓇ Sheds Light on U.S. Consumer Trust in Healthcare and Pharmaceutical Management

Retrieved on: 
Tuesday, December 6, 2022
Hospitals, General Health, Pharmaceutical, Health, Trust, SurveyMonkey, Perception, Human, RFID, Health, Patient, Patient safety, Medication, Hospital, National Center for Medical Intelligence, Pharmacist, Multimedia, Risk, Safety, Nursing, Organization, Pharmaceutical industry, Medicine, Health insurance

This survey brings the voice of the patient to life by highlighting key factors that influence their decision in choosing their healthcare providers.

Key Points: 
  • This survey brings the voice of the patient to life by highlighting key factors that influence their decision in choosing their healthcare providers.
  • Trust in pharmaceutical companies also has a long way to go, with 45.43% of respondents reporting that they do not trust them.
  • Bluesights Patient Perspectives: U.S. Trust in Pharmaceutical Management within Healthcare Systems survey was distributed to U.S. consumers over the age of 18.
  • Through our suite of Medication Intelligence solutions, Bluesight brings simplicity, visibility, and predictability to the complex world of medication management.

Medication Intelligence Leader Kit CheckⓇ Rebrands as BluesightⓇ

Retrieved on: 
Monday, December 5, 2022
Data Management, Health, Technology, Hospitals, Practice Management, Software, General Health, Emergency, Software, Life, BCS, RFID, Patient, Patient safety, Medication, Hospital, Check, Pharmacy, National Center for Medical Intelligence, KLAS, Artificial intelligence, Multimedia, Risk, Safety, Control, Crash, Machine learning, Substance-related disorder, Organization, Medical device, Online shopping, Risk management

Kit Check today announced that it has rebranded as Bluesight , The Medication Intelligence Company, to reflect its comprehensive suite of software solutions, maintaining its commitment to helping hospitals better serve their patients and pursuing a future where the medication supply chain is more efficient and connected.

Key Points: 
  • Kit Check today announced that it has rebranded as Bluesight , The Medication Intelligence Company, to reflect its comprehensive suite of software solutions, maintaining its commitment to helping hospitals better serve their patients and pursuing a future where the medication supply chain is more efficient and connected.
  • Bluesight provides Medication Intelligence solutions to over 1,000 hospital customers, transforming multiple streams of raw data into actionable insights that empower informed decision-making, offering a data-backed way to navigate every touchpoint of the pharmaceutical supply chain.
  • We are thrilled to announce this exciting evolution as we officially rebrand as Bluesight, said Amy Langan, Chief Marketing Officer at Bluesight.
  • Through our suite of Medication Intelligence solutions, Bluesight brings simplicity, visibility, and predictability to the complex world of medication management.

Kit Check Celebrates 1,000 Hospital Customer Milestone

Retrieved on: 
Thursday, October 13, 2022
News, National Center for Medical Intelligence, Becker, ASHP, Hospital, Entrepreneurship, CEO, RFID, Automation, Medical device, KLAS

ALEXANDRIA, Va., Oct. 13, 2022 /PRNewswire/ -- Kit Check, the leading automation vendor in Medication Intelligence™, today announced it has reached over 1,000 hospital customers across the U.S. through its Medication Intelligence solutions –approximately 25% of the estimated 4,600 acute and children's hospitals in the country.

Key Points: 
  • Kit Check, the vendor of medication intelligence solutions, reaches 1000 hospital customer milestone.
  • Kit Check's newest product, Bluesight Insights, is the latest testament to innovation in the hospital space as well as category-creating technologies.
  • To date, Kit Check has partnered with 19 different companies throughout the pharmaceutical supply chain to provide a seamless experience across multiple platforms.
  • To date, our more than 1,000 U.S. and Canadian hospital partners have adopted Kit Check solutions to solve the most challenging of healthcare problems.

Medical Tubing Markets - Global Size, Share, Outlook, and Opportunity Analysis, 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Medical Supplies, Health, National Center for Medical Intelligence, National Center for Biotechnology Information, Application, PP, TPU, Society, Silicone, US, TPE, Diagnosis, Polytetrafluoroethylene, Region, Publication, CAGR, Polyvinyl chloride, PTFE, Polyethylene, Intravenous therapy, Industry, Catheter, PVC, Marketing, Medical device

The medical tubes are available in a variety of shapes and sizes to satisfy demand for medical tubing in various applications.

Key Points: 
  • The medical tubes are available in a variety of shapes and sizes to satisfy demand for medical tubing in various applications.
  • The market players are also focusing on advancements of raw materials of medical tubing, as the materials vary with application and chemical nature of the drug.
  • Silicone is the most preferred material in medical tubing, owing to its higher resistance towards extreme temperatures and non-toxicity.
  • The increasing usage of medical tubing in Intravenous (IVs), catheters, peristaltic pumps, and biopharmaceutical laboratory equipment are expected to boost the medical tubing market growth.

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome

Retrieved on: 
Monday, August 22, 2022
People, Drug overdose, National Center for Medical Intelligence, NCATS, THC, Central nervous system, Patent, National Center for Advancing Translational Sciences, NASDAQ, PMID, Risk, Cannabinoid, USPTO, Drinabant, United Nations, Paranoia, ACO, Anxiety, CHS, Method, Abdominal pain, Dehydration, Gastrointestinal tract, Media, GLOBE, CB-1, FDA, Vomiting, Immune system, Therapy, News, Terminology, Sanofi, Cyclic vomiting syndrome, Nausea, Patient, Pharmaceutical industry, Drug

A Notice of Allowance is issued after the USPTO decides that a patent can be granted from an application.

Key Points: 
  • A Notice of Allowance is issued after the USPTO decides that a patent can be granted from an application.
  • The USPTO issued a Notice of Allowance for U.S. Patent Application 16/904,359, entitled Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist for OPNT004.
  • This patent covers OPNT004 as a method of treatment for CHS using drinabant administered as a parenteral formulation.
  • OPNT004 (drinabant) is a high affinity, CB-1 antagonist for the treatment of excessive cannabinoid use.

Yili Remains the World's Most Valuable Dairy Brand in Brand Finance 2022 Report

Retrieved on: 
Friday, August 12, 2022
National Center for Medical Intelligence, Carbon, FSC, Growth, Yogurt, Intelligence, COVID-19, Food, Test (assessment), RMB, National Medal of Technology and Innovation, Milk, Ice cream, Infant, World, Commercial, Food and Drink, Biodiversity, Satine, Pharmaceutical industry, Renewable energy

HUHHOT, China, Aug. 12, 2022 /PRNewswire/ -- On August 10, Brand Finance, the world's leading brand valuation and strategy consultancy, issued its Food & Drink 2022 report, identifying the most valuable and strongest brands in the food and beverage industries.

Key Points: 
  • HUHHOT, China, Aug. 12, 2022 /PRNewswire/ -- On August 10, Brand Finance, the world's leading brand valuation and strategy consultancy, issued its Food & Drink 2022 report, identifying the most valuable and strongest brands in the food and beverage industries.
  • Yili has been recognized as the World's Most Valuable Dairy Brand, retaining its leading position in the global dairy industry.
  • The National Center of Technology Innovation for Dairy (NCTID) and National Dairy Metrology and Testing Center have also settled into the Valley.
  • As the world's most valuable dairy brand, Yili endeavors to achieve robust corporate growth and drive high-quality industrial development by creating commercial and social value.